Polynovo Ltd

Company Profile

• Business description

  Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita’s RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.

• Contact

  320 Lorimer Street
  Unit 2
  Port MelbourneVIC3207
  AUS

  T: +61 386814050

  https://www.polynovo.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Medical Devices

  Fiscal Year End

  30 June 2025

  Employees

  8